The Exchange had sought clarification from Valiant Laboratories Limited for the quarter ended 30-Sep-2025 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company was required to clarify the following: -1. Segment details not submitted The response of the Company is enclosed.
VALIANTLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The NSE had sought a clarification from Valiant Laboratories regarding its September 2025 quarter results under SEBI's Listing Regulations. The specific query was about the company not submitting segment-wise details as required under Regulation 33. The company has now submitted its response to the exchange. This is a routine reporting-compliance query, not a penalty or enforcement action. No financial impact or regulatory action has been flagged in the filing.
This is a procedural compliance matter with no direct impact on shareholders. Investors may note it reflects a minor reporting lapse on segment disclosures, but the company has responded, keeping the matter routine.